Cardiotoxicity of Cancer Therapies

Authors

Pratik Mondal, New York Medical College
Diwakar Jain, New York Medical CollegeFollow
Wilbert S. Aronow, New York Medical CollegeFollow
William H. Frishman, New York Medical CollegeFollow

DOI

10.1097/CRD.0000000000000239

Journal Title

Cardiology in Review

First Page

230

Last Page

235

Document Type

Article

Publication Date

October 2019

Department

Medicine

Abstract

Cardiotoxicity is a known complication of many cancer therapies. While the cardiotoxicity of established agents such as anthracyclines, antimetabolites, and alkylating agents is well known, it is important to realize that newer anticancer therapies such as tyrosine kinase inhibitors, angiogenesis inhibitors, and checkpoint inhibitors are also associated with significant adverse cardiovascular effects. Echocardiography, magnetic resonance imaging, and radionuclide imaging have been used to identify these complications early and prevent further consequences. We will discuss the different classes of cancer therapeutic agents that cause cardiotoxicity, the mechanisms that lead to these effects, and strategies that can be used to prevent the cardiac morbidity and mortality associated with their use.

Recommended Citation

Mondal, P., Jain, D., Aronow, W., & Frishman, W. (2019). Cardiotoxicity of Cancer Therapies. Cardiology in Review, 27 (5), 230-235. https://doi.org/10.1097/CRD.0000000000000239